AstraZeneca's Fasenra (Benralizumab) Has Been Recommended For Approval In The European Union As An Add-on Treatment For Adult Patients With Relapsing Or Refractory Eosinophilic Granulomatosis With Polyangiitis
Portfolio Pulse from Benzinga Newsdesk
AstraZeneca's Fasenra has been recommended for approval in the EU as an add-on treatment for adult patients with relapsing or refractory eosinophilic granulomatosis with polyangiitis. The recommendation is based on the MANDARA Phase III trial results.
September 23, 2024 | 10:49 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
AstraZeneca's Fasenra has been recommended for EU approval as an add-on treatment for EGPA, based on positive results from the MANDARA Phase III trial.
The recommendation for EU approval of Fasenra as an add-on treatment for EGPA is a significant development for AstraZeneca. The positive results from the MANDARA Phase III trial, which showed Fasenra's efficacy and safety, enhance the drug's market potential. This could lead to increased sales and revenue for AstraZeneca, positively impacting its stock price in the short term.
CONFIDENCE 95
IMPORTANCE 80
RELEVANCE 90